The Future of Healthcare Reimbursement: What to Expect in the Next 5 Years

Healthcare reimbursement is entering a period of structural change. Margin compression, regulatory pressure, and increasingly sophisticated payor strategies are forcing providers—particularly multisite and private equity-backed platforms—to rethink how revenue is generated, negotiated, and sustained.

The next five years will not be defined by a single reimbursement model winning out. Instead, we will see a hybrid environment where Fee-For-Service (FFS) and Value-Based Care (VBC) coexist—but with sharper economics, tighter contracts, and far less room for operational inefficiency.

For operators and investors, the implication is clear: reimbursement strategy is no longer a back-office function. It is a primary driver of EBITDA, valuation, and scalability.

1. Fee-For-Service Isn’t Going Away—But It Will Get Smarter

Despite years of predictions about its decline, FFS will remain a foundational revenue model. However, payors are becoming far more disciplined in how they structure and manage these contracts.

What’s changing:

• Narrower rate variation across providers within markets

• Increased use of data benchmarking during negotiations

• More aggressive utilization management and denial patterns

  
  

What it means commercially:

Providers that rely on legacy contracts or passive renegotiation cycles will see gradual rate compression. In contrast, groups that actively leverage market data and understand their relative value proposition can still drive meaningful rate uplift.

Operator takeaway:

FFS optimization is becoming a data-driven exercise. Groups need clear visibility into local rate benchmarks, service line profitability, and payor behavior to maintain margin.

2. Value-Based Care Will Expand—But Selectively

VBC adoption will continue, but not uniformly across specialties or geographies. The next phase will favor models that demonstrate measurable cost control and outcomes improvement—not just participation.

Where we’ll see growth:

• Primary care and care coordination-heavy specialties

• Bundled payments for defined episodes of care

• Risk-sharing arrangements with downside accountability

Where adoption will lag:

• Procedural specialties without longitudinal patient engagement

• Fragmented provider markets lacking scale

What it means commercially:

VBC will create upside opportunities—but also introduce earnings volatility. Poorly structured arrangements can erode margins quickly if cost controls and attribution models are not tightly managed.

Operator takeaway:

Success in VBC requires infrastructure: data analytics, care management workflows, and contract sophistication. Without these, participation can dilute rather than enhance profitability.

3. Price Transparency Will Reshape Negotiation Leverage

Price transparency is moving from a compliance exercise to a competitive weapon. Payors and employers are increasingly using this data to steer patients and challenge provider pricing.

What’s changing:

• Publicly available negotiated rate data across markets

• Employer-driven demand for cost predictability

• Increased scrutiny of outlier pricing

What it means commercially:

Providers with above-market rates but no clear differentiation will face downward pressure. Conversely, groups that can demonstrate quality, access, or unique capabilities can justify premium positioning.

Operator takeaway:

Price transparency data should be actively incorporated into negotiation strategy—not ignored. It provides both a defensive tool and an offensive opportunity when used correctly.

4. Payor Consolidation Will Increase Pressure on Providers

Market concentration among payors continues to rise, strengthening their negotiating leverage—particularly in regional markets.

Implications:

• Fewer counterparties with greater pricing power

• Standardized contract structures across larger populations

• Reduced flexibility in negotiations for smaller providers

What it means commercially:Independent practices and smaller platforms will find it increasingly difficult to achieve favorable terms without scale or differentiation.

Operator takeaway:

Scale matters more than ever—but so does positioning. Providers must clearly articulate their value (access, outcomes, patient experience) to counterbalance payor leverage.

5. Revenue Cycle Performance Will Become a Strategic Lever

As reimbursement tightens, the ability to collect every dollar earned becomes critical. Revenue cycle management (RCM) is shifting from an operational necessity to a strategic differentiator.

Key trends:

• Increased automation and AI-driven coding/collections

• More complex denial management requirements

• Greater integration between clinical and financial workflows

What it means commercially:

Even small improvements in net collection rates can translate into significant EBITDA gains—often faster than contract renegotiation alone.

Operator takeaway:

Top-performing organizations treat RCM as a core competency, not an outsourced afterthought.

6. Hybrid Reimbursement Models Will Dominate

The future is not FFS or VBC—it’s both, layered together in increasingly complex ways.

Providers will manage:

• FFS contracts with performance-based incentives

• Partial-risk VBC arrangements

• Bundled payments for select procedures

What it means commercially:

This hybrid environment increases both opportunity and complexity. Organizations that can model, forecast, and optimize across multiple reimbursement streams will outperform peers.

Operator takeaway:

Financial and operational alignment is critical. Silos between contracting, finance, and clinical operations will limit performance.

What This Means for Private Equity and Growth-Oriented Platforms

For investors and operators, reimbursement strategy is now central to the investment thesis.

Over the next five years:

• EBITDA expansion will increasingly come from rate optimization and RCM performance, not just organic volume growth

• Platform scalability will depend on contracting sophistication and payor alignment

• Valuation premiums will favor groups with demonstrable reimbursement advantage

In short, reimbursement is becoming a core value creation lever, not just a constraint to manage.

Final Thought: Strategy Will Separate Winners from Survivors

The reimbursement environment is not becoming unworkable—it’s becoming more disciplined.

Organizations that take a passive approach will experience gradual margin erosion. Those that invest in data, contracting expertise, and operational alignment will find meaningful upside—even in a tightening market.

How Accretive Health Advisors Helps

Accretive Health Advisors partners with provider organizations and investors to turn reimbursement into a strategic advantage. Through disciplined FFS and VBC contract negotiation, price transparency analytics, and revenue optimization strategies, we help clients:

• Expand EBITDA through improved payor rates

• Strengthen cash flow via enhanced RCM performance

• Position platforms for scalable, high-multiple growth

The next five years will reward precision. We help you execute it.